Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician

(2017) Paresh Dandona et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus

(2017) V. Sahasrabudhe et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

SGLT2 Inhibitors and the Diabetic Kidney

(2016) Paola Fioretto et al.   DIABETES CARE

Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition

(2016) Volker Vallon et al.   DIABETOLOGIA

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy

(2014) Hala Yamout et al.   AMERICAN JOURNAL OF NEPHROLOGY

Clinical Pharmacokinetics and Pharmacodynamics of the Novel SGLT2 Inhibitor Ipragliflozin

(2014) Takeshi Kadokura et al.   CLINICAL PHARMACOKINETICS

Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

(2014) André J. Scheen   DRUGS

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

(2014) Anthony H Barnett et al.   Lancet Diabetes & Endocrinology

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

(2013) David Z.I. Cherney et al.   CIRCULATION

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment

(2013) S. Macha et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

(2013) J.-F. Yale et al.   DIABETES OBESITY & METABOLISM

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

(2013) Donald E. Kohan et al.   KIDNEY INTERNATIONAL

Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors

(2011) Vincent Mascitti et al.   JOURNAL OF MEDICINAL CHEMISTRY

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

(2008) J. F. List et al.   DIABETES CARE